



Sequella, Inc.  
9610 Medical Center Drive  
Rockville, MD 20850  
Tele: 301-762-7776  
[www.sequella.com](http://www.sequella.com)

## ***NEWS RELEASE***

### **Sequella Hires Director of Finance**

ROCKVILLE, Md, January 12, 2006-- Sequella, Inc., a privately held biotechnology company developing products for infectious disease, is pleased to announce that Marty Zug has joined the company as Director of Finance. He will be responsible for financial and accounting operations. As a consultant to Sequella this past year, Mr. Zug negotiated National Institutes of Health (NIH) cost accounting rates, and managed financial strategy and budgeting. He will continue to work in these areas, and play a larger role in raising capital and managing investor relations.

Prior to joining Sequella, Mr. Zug was a Vice President of the Washington Redskins, where he managed business lines totaling over \$45 million in revenue. Prior to the Redskins, he was a Director for Snyder Communications, where he focused on financial, strategic, and investor relations and communications issues. He was also involved in the sale of this publicly traded company to Havas Advertising for \$2.1 billion. Mr. Zug started his career in Russia, where he worked in investment banking for newly privatized Russian companies. During this time, he was part of the banking team that closed the largest private financing of a Russian company in 1995 and the first syndicated loan in Russia. He holds an MBA from the Amos Tuck School of Business at Dartmouth College.

“We are delighted to have Marty join our team. His extensive experience in corporate finance and investment banking adds depth and leadership to Sequella as we enter an exciting and dynamic phase of growth. He will establish the internal controls, and financial and accounting systems to enable us to meet our corporate objectives as we move more R&D assets into clinic this upcoming year,” said Dr. Carol Nacy, CEO of Sequella.

#### **About Sequella, Inc.**

Sequella is a clinical stage biotechnology company that develops and commercializes novel infectious disease products. Sequella conducts discovery and pre-clinical research at its Rockville, Md headquarters, which houses chemistry and microbiology laboratories. Sequella advances new and more effective products for high hazard microorganisms in its BioSafety Level-3 (BSL-3) facility. Our lead product candidate, the Transdermal Patch for diagnosis of TB disease, is completing an international phase III clinical trial in Peru and we expect to file for worldwide registration by 2007. The Sequella antibiotic drug discovery research program focuses on novel small molecule and natural product-based drugs. Our first drug candidate, a new diamine antibiotic SQ109, has completed IND-enabling preclinical toxicology studies.

For more information, please visit [www.sequella.com](http://www.sequella.com)

#### **Media Contact:**

Corporate Development  
Sequella, Inc.  
9610 Medical Center Drive, Suite 200  
Rockville, MD 20850  
301-762-7776 (phone); 301-762-7778 (fax)